Cargando…

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy

Lipegfilgrastim is a long-acting, once-per-cycle, glycopegylated recombinant granulocyte colony-stimulating factor (G-CSF) used to prevent neutropenia in patients receiving myelosuppressive chemotherapy. This integrated analysis examined the immunogenicity of lipegfilgrastim and its potential clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Linglong, Buchner, Anton, Roberge, Martin, Liu, Patrick M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935921/ https://www.ncbi.nlm.nih.gov/pubmed/27419145 http://dx.doi.org/10.1155/2016/9248061

Ejemplares similares

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
por: Bondarenko, Igor, et al.
Publicado: (2013)

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy
por: Buchner, Anton, et al.
Publicado: (2014)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia, Roberto, et al.
Publicado: (2016)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Review on lipegfilgrastim
por: Gasparic, Maja, et al.
Publicado: (2015)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
por: Volovat, Constantin, et al.
Publicado: (2015)

A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma
por: Belogurova, Margarita B., et al.
Publicado: (2016)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting
por: Merseburger, Axel S., et al.
Publicado: (2021)

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
por: Bond, T Christopher, et al.
Publicado: (2017)

Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
por: Lehmacher, W., et al.
Publicado: (2016)

Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe
por: Kaplan, Sigal, et al.
Publicado: (2019)

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial
por: Tjulandin, Sergei A, et al.
Publicado: (2010)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

Difference in Immunogenic Responses to COVID-19 Vaccines in Patients With Cancer Receiving Chemotherapy Versus Nonchemotherapy Treatment
por: Tantiyavarong, Walaipan, et al.
Publicado: (2023)

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial
por: Tjulandin, Sergei A, et al.
Publicado: (2011)

Assessment of the Predictive Role of Serum Lipid Profiles in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Qu, Fanli, et al.
Publicado: (2020)

Modulation of Interhemispheric Functional Coordination in Breast Cancer Patients Receiving Chemotherapy
por: Tao, Longxiang, et al.
Publicado: (2020)

Reliability and Validity of the Turkish Version of Chemotherapy-induced Peripheral Neuropathy Assessment Tool for Breast Cancer Patients Receiving Taxane Chemotherapy
por: Simsek, Neriman Yükseltürk, et al.
Publicado: (2018)

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
por: Pfeil, Alena M, et al.
Publicado: (2014)

Effect of therapeutic care for treating fatigue in patients with breast cancer receiving chemotherapy
por: Zhang, Bing, et al.
Publicado: (2017)

The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
por: Zhou, Wenbin, et al.
Publicado: (2012)

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen
por: Dong, Zhaoying, et al.
Publicado: (2021)

Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy
por: do Nascimento, Talita Garcia, et al.
Publicado: (2014)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
por: Cao, Maria D, et al.
Publicado: (2012)

Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy
por: Muthanna, Fares Mohammed Saeed, et al.
Publicado: (2021)

Cognitive impairment and elevated peripheral cytokines in breast cancer patients receiving chemotherapy
por: Khan, Mohd Ashif, et al.
Publicado: (2022)

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy
por: Hatse, Sigrid, et al.
Publicado: (2022)

Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
por: Yao, Senbang, et al.
Publicado: (2022)

Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice
por: Zhang, Jinguo, et al.
Publicado: (2022)

Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma
por: Aoto, Keita, et al.
Publicado: (2018)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
por: Pierga, J-Y, et al.
Publicado: (2007)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy
por: Jakabova, Anna, et al.
Publicado: (2021)

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_903582f5k9skmi86km6svetcqe